Navigation Links
European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed

COLUMBIA, Md., Nov. 15 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that the Opposition Division of the European Patent Office (EPO) has ruled in favor of Martek and upheld one of the Company's European docosahexaenoic acid (DHA) patents. The modified claims of the patent are narrower than the claims originally granted but broader than the claims that were previously upheld in a December 2000 Opposition Division hearing. The patent, which expires in November 2010, relates to fermentation processes, human and animal food products, pharmaceutical uses of certain claimed microorganisms, and Martek's food DHA production strain.

Fermentation process claims in the patent that provide important commercial protection for Martek were upheld by the EPO, while certain product claims were narrowed by the elimination of coverage for extracted DHA oil. These fermentation process claims are not limited to any particular use of the DHA oil, i.e., they are relevant if the oils from the claimed processes are used in food or nonfood applications, such as human and animal foods, supplements, and pharmaceuticals. The Company believes that, on an overall basis, the patent as modified remains an important part of the Company's intellectual property portfolio and that the narrowing of the claims of the patent should not have any material adverse impact on the Company.

The patent was the subject of a challenge by Aventis Research and Technologies GmbH & Co. KG, and Nagase Limited. The Company believes that it is probable that at least one of the opponents of the patent will appeal the Opposition Division's decision. If an appeal is made, the Appeal Board hearing would be anticipated to occur in about two years.

About Martek Biosciences

Martek Biosciences Corporation (NASDAQ: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The Company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit

Forward-Looking Statements

Sections of this release contain forward-looking statements, including, without limitation, statements concerning the course and outcome of current and future legal proceedings and the strength of Martek's patent portfolio. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. For instance, Martek cannot predict with certainty any events associated with the EPO appeal process, the future actions of Martek's customers or competitors or prospective customers or competitors or the competitive and financial impact of any final EPO decision on the value of Martek's intellectual property. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Forms 8-K, 10-Q and 10-K.


Cassie France-Kelly

Public Relations, Martek

(443) 542-2116

Kyle Stults

Investor Relations, Martek

(410) 740-0081

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
Breaking Biology News(10 mins):